-
Cencora (COR) Tops Q4 EPS by 4c, provides guidance
-
Morgan Stanley Upgrades Cencora Inc (COR) to Overweight
-
Jefferies Upgrades Cencora Inc (COR) to Buy
-
Cencora secures $4.5 billion in credit facilities for OneOncology acquisition
-
Cencora Inc (COR) PT Lowered to $360 at BofA Securities
-
Cencora Inc (COR) PT Raised to $420 at Evercore ISI
-
Cencora to acquire majority stake in OneOncology for $3.6 billion
-
These are the best U.S. healthcare tech and distribution stocks to buy: Barclays
-
Cencora Inc (COR) PT Raised to $400 at TD Cowen
-
Cencora Inc (COR) PT Raised to $415 at UBS
-
Cencora Inc (COR) PT Raised to $410 at Leerink Partners
-
Cencora (COR) Tops Q3 EPS by 5c
-
Cencora (COR) 2900 contracts of November 320 calls trade
-
Cencora Inc (COR) PT Raised to $354 at Wells Fargo
-
Cencora (COR) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY25 EPS Guidance
-
Mizuho Reiterates Outperform Rating on Cencora Inc (COR)
-
Wells Fargo Upgrades Cencora Inc (COR) to Overweight
-
Cencora (COR) Appoints Lori J. Ryerkerk to Its Board
-
Cencora (COR) Tops Q1 EPS by 36c, provides guidance
-
Cencora Inc (COR) PT Raised to $305 at Mizuho
-
Logistics Firm Walden Said To Draw Interest From DHL, Cencora (COR) - Bloomberg
-
Increasing unusual put option volume: MLCO UAA IBB NWL EWC BILL COR ANAB BDX BBAI SMTC FEZ
-
Cencora Inc (COR) PT Raised to $301 at Leerink Partners
-
Cencora (COR) Tops Q4 EPS by 24c, raises guidance
-
Cencora (COR) Completes Acquisition of Retina Consultants of America
-
Mizuho Starts Cencora Inc (COR) at Outperform
-
Cencora Inc (COR) PT Raised to $260 at BofA Securities
-
Cencora (COR) Files Mixed Shelf
-
Cencora (COR) Tops Q3 EPS by 12c, Beats on Revenue
-
Cencora (COR) Acquires Retina Consultants of America
-
The election implications for healthcare technology and distribution stocks - BofA
-
Citi Reiterates Buy Rating on Cencora Inc (COR) Following Ransom Payment of $75M
-
Cencora (COR) Hackers Were Paid $75 Million In Largest Known Ransom - Bloomberg
-
Cencora Inc (COR) PT Lowered to $245 at BofA Securities, Downgrade to Neutral
-
Cencora Inc (COR) PT Lowered to $283 at Baird
-
TD Cowen Reiterates Buy Rating on Cencora Inc (COR)
-
CoreSite Realty (COR) Appoints Frank Clyburn to Its Board
-
Cencora Inc (COR) PT Raised to $284 at Citi
-
Cencora (COR) Tops Q2 EPS by 12c; raises guidance
-
Cencora Inc (COR) PT Raised to $285 at Baird
-
Outlook Therapeutics (OTLK) Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
-
Walgreens Boosts Alliance (WBA) PT Lowered to $11 at Barclays
-
Midday movers: Micron, Levi Strauss, Walgreens and International Paper fall

